PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses change of 100.00% while RVPH maintains costs. Bruce Berkowitz would investigate efficiency.
752.87%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
752.87%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
22.99%
Interest expense growth while RVPH reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
-552.87%
EBITDA decline while RVPH shows 5.85% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-552.87%
Operating income decline while RVPH shows 7.11% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
675.86%
Tax expense growth above 1.5x RVPH's 52.58%. Michael Burry would check for concerning trends.
-675.86%
Net income decline while RVPH shows 5.90% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-2175.00%
EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
-2175.00%
Diluted EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
-66.67%
Share count reduction while RVPH shows 2.47% change. Joel Greenblatt would examine strategy.
-66.67%
Diluted share reduction while RVPH shows 2.47% change. Joel Greenblatt would examine strategy.